Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00163059 | The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD | PHASE2 | COMPLETED | 30 | — | — | May 1, 2004 | Dec 1, 2005 | Sep 22, 2006 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| NMDA Antagonist, CP-101,606 (traxoprodil) | DRUG | - |
Inclusion Criteria: * Primary DSM-IV diagnosis of MDD Exclusion Criteria: * Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, bu...